Medical/Pharmaceuticals
TraceLink MINT Wins 2023 Pharma Innovation Award: 100% End-to-End Supply Chain Digitalization is Now Within Reach
100% End-to-End Supply Chain Digitalization is Now Possible with Proven Network Orchestration Capability BOSTON, Nov. 2, 2023 /PRNewswire/ -- TraceLink Inc., the leading digital network platform company enabling end-to-end product orchestration by connecting more than 291,000 healthcare and life...
2023-11-02 05:22
1750
Sirnaomics Presents Positive Clinical Data of STP705 for Focal Fat Reduction
The Group is Advancing the Program to a Phase II Clinical Study Data presented at the 2023 Fall Clinical Dermatology Conference HONG KONG and GERMANTOWN, Md. and SUZHOU BIOBAY, China, Nov. 1, 2023 /PRNewswire/ --Sirnaomics Ltd. (the "Company", Stock Code: 2257.HK, together with its subsidiaries,...
2023-11-01 22:07
2179
Johnson & Johnson Innovation Launches Singapore QuickFire Challenge with the Singapore Economic Development Board
Following launch of first-of-its-kind collaboration between Johnson & Johnson Innovation – JLABS andSingapore's Economic Development Board, the Singapore QuickFire Challenge invites innovators to pitch for grant funding from a pool of $100,000 for further development. SINGAPORE, Nov. 1, 2023 /PRN...
2023-11-01 22:05
2091
Milliken & Company Launches OVIK Health
Company rebrands healthcare business as a strategic enabler SPARTANBURG, S.C., Nov. 1, 2023 /PRNewswire/ -- Today, global diversified manufacturer Milliken & Company unveiled a new brand platform for its healthcare business. OVIK Health, as Milliken Healthcare Products, LLC, will now be known, r...
2023-11-01 21:38
2298
SIBIONICS Achieves Milestone: Receiving CE Mark for Its Groundbreaking GS1 Continuous Glucose Monitoring System
SHENZHEN, China, Nov. 1, 2023 /PRNewswire/ -- SIBIONICS, the world's third-largest Continuous Glucose Monitoring System (CGM) brand, is delighted to announce that it has received the CE Mark for its revolutionary GS1 CGM. This significant milestone marks a momentous achievement for SIBIONICS, fac...
2023-11-01 20:28
3104
CStone Announces Strategic Partnership and Exclusive Licensing Agreement with 3SBio for Nofazinlimab (Anti-PD-1 Antibody) in Mainland China
* CStone to grant 3SBio exclusive rights for the development, registration, manufacturing, and commercialization of nofazinlimab (anti-PD-1 antibody) in mainlandChina. CStone to retain the rights to nofazinlimab outside mainland China. * This partnership will combine the strengths of CStone a...
2023-11-01 18:10
3354
AXA BetterMe Weekend concludes in high note, drawing over 12,000 participants
Two-day carnival inspires physical and mental well-being Allowing citizens to unwind and rejuvenate to become a BetterMe HONG KONG, Nov. 1, 2023 /PRNewswire/ -- AXA BetterMe Weekend, the iconic annual carnival hosted by AXA Hong Kong andMacau (AXA) on 28 and 29 October 2023, was a resounding succ...
2023-11-01 18:02
2099
P&G Health commemorates World Diabetes Day 2023 with innovative AI-based Experiential Campaign #KnowtheSigns
* 1 in 2 Diabetics and 1 in 10 Pre-diabetics estimated to suffer from Peripheral Neuropathy * Vitamin B Deficiency affects quality of life of ~ 19% of all people with diabetes * #KnowtheSigns leverages Artificial Intelligence to make the invisible condition of Peripheral Neuropathy & Vitami...
2023-11-01 14:00
1970
Extracellular Nanoparticles Sourced From Another Species Reverses Biological Age of Rats by More Than 50%
Peer Reviewed Publication: World's first demonstration of cross species epigenetic transfer that significantly reverses biological age by Scientists at Yuvan Research. MOUNTAIN VIEW, Calif., Nov. 1, 2023 /PRNewswire/ -- In a groundbreaking research paper titled"Reversal of Biological Age in Mult...
2023-11-01 09:14
1235
Soterios Pharma completes Phase II enrolment for STS-01 in mild / moderate (patchy) alopecia areata
LONDON, Nov. 1, 2023 /PRNewswire/ -- Soterios Pharma, a privately held clinical-stage pharmaceutical company, announced today that it has completed target enrolment for its Phase II trial with STS-01 for mild / moderate (patchy) alopecia areata. Final results of the study are anticipated to be ...
2023-11-01 09:05
1063
Antengene Presents Results from Five Investigational Programs at 2023 SITC Annual Meeting
SHANGHAI and HONG KONG, Nov. 1, 2023 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for cancer...
2023-11-01 08:30
1560
88th CMEF Unveils Cutting-Edge Medical Breakthroughs in Shenzhen, Unleashing the Latest Medical Technologies and Solutions
SHENZHEN, China, Oct. 31, 2023 /PRNewswire/ -- The 88th China International Medical Equipment Fair (CMEF) officially kicks off onOctober 28 at the Shenzhen World Exhibition & Convention Center. The four-day tradeshow will feature over 10,000 products brought by over 4,000 exhibitors from more tha...
2023-10-31 21:34
2241
BioLineRx Entered Exclusive License Agreement to Motixafortide in Asia, Advised by MSQ Ventures
NEW YORK, Oct. 31, 2023 /PRNewswire/ -- MSQ Ventures ("MSQ") is pleased to announce that its client, BioLineRx Ltd. ("BioLineRx") (NASDAQ/TASE: BLRX), has entered into an exclusive license agreement with Guangzhou Gloria Biosciences Co., Ltd. (GloriaBio) and an associated investor for the deve...
2023-10-31 21:00
3289
YS Biopharma Announces Completion of Subject Enrollment in Pivotal Phase 3 Clinical Trial of PIKA Rabies Vaccine
GAITHERSBURG, Md., Oct. 31, 2023 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious disea...
2023-10-31 20:30
1474
HOYA Vision Care Releases One-Year MiYOSMART European Study Results
Initial evidence-based findings of three-year study strongly supports MiYOSMART portfolio BANGKOK, Oct. 31, 2023 /PRNewswire/ -- HOYA Vision Care, committed to developing innovative solutions to address the growing problem of myopia progression in children, extended its research toEurope in an ...
2023-10-31 19:13
1774
Select the Right Medical-Grade TPU：ICP DAS - BMP Launches a New TPU Series at COMPAMED & IPF Japan 2023
HSINCHU, Oct. 31, 2023 /PRNewswire/ -- ICP DAS – Biomedical Polymers, Asia's first medical-grade TPU (thermoplastic polyurethane) manufacturer and supplier, will be exhibiting at COMPAMED inGermany and IPF in Japan in November and December 2023. The company proudly presents its new Arothane™ ARP-...
2023-10-31 16:38
2057
Biotechnology Start-Up Psylo Wins Hello Tomorrow APAC Deep Tech Competition in Singapore
SINGAPORE, Oct. 31, 2023 /PRNewswire/ -- Psylo, a biotechnology start-up pioneering the development of next-generation serotonergic agents for the treatment of central nervous system (CNS) disorders, today announced that it won the Hello Tomorrow APAC deep tech competition held inSingapore. The ...
2023-10-31 15:42
1771
CStone Announces NMPA Approval of Sugemalimab for Patients with Relapsed or Refractory Extranodal NK/T-cell Lymphoma, the First Anti-PD-1/PD-L1 mAb Approved for this Indication
* Sugemalimab is the world's first anti-PD-1/PD-L1 monoclonal antibody approved for relapsed or refractory extranodal NK/T-cell lymphoma (R/R ENKTL) indication. * This marks sugemalimab's third indication approved in China following Stage III and IV non-small cell lung cancer (NSCLC) and the ...
2023-10-31 10:16
2261
AffaMed Therapeutics Announced Positive Top-Line Results from Real-World Study in China Evaluating the Safety and Efficacy of DEXTENZA® in Patients after Cataract Surgery
SHANGHAI, Oct. 31, 2023 /PRNewswire/ -- AffaMed Therapeutics ("AffaMed"), a global biotechnology company dedicated to developing and commercializing transformative pharmaceutical, digital and surgical products that address critical unmet medical needs in ophthalmological, neurological and psychia...
2023-10-31 09:35
2109
SK Life Science Labs, a Subsidiary of SK Biopharmaceuticals, Presents Discovery of Oral SMARCA2 Degraders Data at 6th Annual Targeted Protein Degradation Summit
Preclinical data show SK Life Science Labs compounds have robust anti-tumor efficacy in vivo and oral leads have demonstrated potent selective degradation of SMARCA2 with selective inhibition of proliferation of SMARCA4 mutant cells KING OF PRUSSIA, Pa., Oct. 31, 2023 /PRNewswire/ -- SK Life Scie...
2023-10-31 08:00
1686
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 314 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
2024-11-20 16:30
7433
Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
2024-11-20 09:00
6834
